All In Biotech

NDA 017556 · Sun Pharm Inds INC

Halog

Halcinonide · Topical · Corticosteroid

Novel

Last checked: Nov 20, 2026Latest source record: Apr 2, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1974

Nov 27, 1974

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 1 recruiting

FAERS reports

194

59 serious, 8 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 15, 2026.

INDICATIONS AND USAGE HALOG (Halcinonide Cream, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 27, 1974 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • HALOG · HALCINONIDE 0.1% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Halcinonide" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective23
  • psoriasis19
  • rash16
  • pain13
  • pruritus13
  • arthralgia12
  • diarrhoea10
  • headache10
  • nausea10
  • fatigue9
  • off label use9
  • condition aggravated7

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20092
20103
20112
20127
20138
20146
201515
201618
201733
201817
201913
202015
202115
202215
202313
20244
20252
20265

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 40 on PubMed

Sponsor: Sun Pharm Inds INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.